Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: An open-label, pilot study

Journal of Affective Disorders

Volumn 117, Issue 1-2, 2009, Pages 116-119

  Anderson, I M ^a   Sarsfield, A ^a   Haddad, P M ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antidepressant; Atypical antipsychotic; Augmentation; Monoamine reuptake inhibitor; Quetiapine; Treatment resistant depression

Indexed keywords

OLANZAPINE; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DIZZINESS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 67650086542     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.12.016     Document Type: Article

References (16)

1. Anderson I.M., Ferrier I.N., Baldwin R.C., Cowen P.J., Howard L., Lewis G., Matthews K., McAllister-Williams R.H., Peveler R.C., Scott J., and Tylee A. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J. Psychopharmacol. 22 (2008) 343-396
2. Calabrese J.R., Keck P.E., MacFadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., and Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatr. 162 (2005) 1351-1360
3. Corya S.A., Williamson D., Sanger T.M., Briggs S.D., Case M., and Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety 23 (2006) 364-372
4. Dannlowski U., Baune B.T., Böckermann I., Domschke K., Evers S., Arolt V., Hetzel G., and Rothermundt M. Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Hum. Psychopharmacol. 23 (2008) 587-593
5. Dorée J.-P., Rosiers J.D., Lew V., Gendron A., Elie R., Stip E., Emmanuel T.S., and Tourjman S.V. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr. Med. Res. Opin. 23 (2007) 333-341
6. Guy W. ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education and Welfare publication (ADM) (1976), National Institute of Mental Health, Rockville MD
7. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., and Roth B.L. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33 (2008) 2303-2312
8. McIntyre A., Gendron A., and McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress. Anxiety 24 (2007) 487-494
9. Montgomery S.A., and Åsberg M.A. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
10. Olver J.S., Ignatiadis S., Maruff P., Burrows G.D., and Norman T.R. Quetiapine augmentation in depressed patients with partial response to antidepressants. Hum. Psychopharmacol. 23 (2008) 653-660
11. Papakostas G.I., Shelton R.C., Smith J., and Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J. Clin. Psychiatry 68 (2007) 826-831
12. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., and Rosenbaum J.F. Acute and longer term outcomes in depressed patients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatr. 163 (2006) 1905-1917
13. Sagud M., Mihaljević-Peles A., Mück-Seler D., Jakovljević M., and Pivac N. Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology 187 (2006) 511-514
14. Shelton R.C., Williamson D.J., Corya S.A., Sanger T.M., Van Campen L.E., Case M., Briggs S.D., and Tollefson G.D. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry 66 (2005) 1289-1297
15. Snaith R.P., Baugh S.J., and Clayden A.D. The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br. J. Psychiatry 141 (1982) 518-523
16. Thase M.E., Macfadden W., Weisler R.H., Chang W., Paulsson B., Khan A., Calabrese J.R., and BOLDER II Study Group. Abstract: efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo controlled study (the BOLDER II study). J. Clin. Psychopharmacol. 26 (2006) 600-609